10
To improve the effectiveness and tolerability of the three times per week therapeutic schedule of IFN, two forms of pegylated interferon (PEG-IFN) were developed in the early 2000s—PEG-IFN-α2a and PEG-IFN-α2b
Measurements: Sustained virologic response rate and adverse event-related withdrawal rate
Until 2011, the standard of care for HCV chronic infection was based exclusively on the combination of pegylated interferon alpha (IFNα) and ribavirin (RBV) administered for 24/48 weeks with A 4-week induction with pegylated interferon-α2a plus ribavirin was associated with a greater decrease in HCV RNA at week 4; however, this did not translate into higher EVR rates
Successful clearance of hepatitis C virus with pegylated interferon α-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis Ann Rheum Dis
139824
Gastroenterology 118, Background: Amino acid variations in several HCV genomic regions have been reported to be associated with response to interferon (IFN)-α plus ribavirin (RBV) combination therapy
A 34-year-old white woman with chronic hepatitis C virus infection who was treated with pegylated interferon α-2a and ribavirin, developed Grave's disease and autoimmune hepatitis (AIH) at 32 and 44 weeks, respectively, following initiation of
In total, 18% of patients treated for 24 weeks Pegylated interferon-α2a (PEG-IFN-α2a) and pegylated interferon-α2b (PEG-IFN-α2b), which are used to treat patients with chronic hepatitis C virus (HCV) or B virus (HBV) infection, are modified IFNs that have longer serum half-life in body than non-pegylated forms of IFNs, therefore they can be given to patients only once a week
Roberto J Carvalho-Filho 1 Division of Gastroenterology, Hepatitis (≤800,000 IU/mL) viral load
(2014) also suggested that short-term subcutaneous pegylated IFN-α in combination with oral ribavirin treatment rapidly decreased RV RNA in recurrent or chronic rhinovirus PEG-ifN-α2a or PEG-IFN- α2b + ribavirin combination therapies showed similar efficacies and tolerabilities as initial treatments for chronic hepatitis C
Methods: This randomized, double-blind, placebo-controlled, ascending-dose study investigated the antiviral activity, safety and pharmacokinetics of IDX184 plus pegylated interferon-α2a and ribavirin (P/R) in treatment-naive patients with genotype